RxDoctor Payments Data

Timothy Allen, DO

Internal Medicine · Burleson, TXNPI 1033172499

Payments from drug & device makers

$1,076in general payments, 2019–2025

Across 62 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • AbbVie$163
  • Acadia Pharmaceuticals Inc$153
  • Otsuka America Pharmaceutical, Inc.$122
  • Merck$87
  • Abbott$72
  • plus $255 from 9 others

What the payments were for

  • Food & beverage$1,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,076 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$71,455
Medicare patients
124
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$76,965
JanuviaSitagliptin Phosphate58$37,980
OzempicSemaglutide22$36,398
MounjaroTirzepatide16$18,755
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,542
JardianceEmpagliflozin12$7,380
Breo ElliptaFluticasone/Vilanterol12$4,731
SymbicortBudesonide/Formoterol Fumarate12$3,595
Albuterol Sulfate HfaAlbuterol Sulfate82$2,391
Pantoprazole Sodium188$2,242
Gabapentin151$1,694
Telmisartan64$1,513
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid29$1,459
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,372
Levothyroxine Sodium152$1,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$87$37,98058 claims
Novo NordiskOzempic$225$36,39822 claims
Lilly USA, LLCMounjaro$50$18,75516 claims
Boehringer IngelheimJardiance$26$7,38012 claims
GSKBreo Ellipta$37$4,73112 claims
AbbVieSynthroid$163$98825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →